Programmpunkt

10:45

Titel: Donor screening and acquisition for the production of COVID-19 convalescent plasma using a specific hotline questionnaire
ID: VS-3-4
Art: Abstractvortrag
Redezeit: 10 + 5 min
Session:
ARGE Plasmapherese
VS-3

Referent: Andreas Brosig (Regensburg)


Abstract - Text

Offenlegung Interessenkonflikt:

-

Methods

First a call for plasma donors already recovered from COVID-19 was published on the UKR's social media accounts together with the hotline number. Potential donors were interviewed by trained students using our questionnaire based on the PEI's "Uniform Blood and Plasma Donor Questionnaire" and PEI's eligibility criteria specific for COVID-19 convalescents. The evaluation of the questionnaires was performed by the medical staff. Possible plasma donors were invited for SARS-CoV-2 PCR testing as two negative results were needed. Callers meeting all criteria so far were invited for an on-site donor qualification and - when available later on - for an Anti-Sars-CoV-2 antibody screening using a quantitative ELISA (Inst. of Med. Mic. and Hyg.).

Results

Applying our questionnaire, from 1240 callers 824 (66.5%) were screened out from the hotline directly while 416 (33.5%) completed the questionnaire successfully. Using this information medical staff screened out 144 of these 416. Another 82 didn't meet eligibility criteria at first, so 190 of 416 callers were considered for plasma donation. Subsequently 10 of these 82 met eligibility criteria and increased the number of possible donors to 200. We evaluated 57 of these 200 on-site for donor qualification and finally qualified 20 donors with a suitable antibody titer: 1:400 (n=8) and ≥1:800 (n=12). Another 81 of 200 were directly tested for Anti-SARS-CoV-2 antibodies: 31 had a suitable titer of ≥1:800 but were not yet checked on-site.

Background

COVID-19 caused by SARS-CoV-2 can result in severe or even life-threatening respiratory symptoms. With no approved treatment available anti-SARS-CoV-2 antibody rich plasma from COVID-19 convalescents emerged as a potential option in treating COVID-19. With the acquisition of plasma donors meeting the eligibility criteria most likely being highly time consuming we designed a specific questionnaire for a telephone hotline screening. Here we present the initial results from the first three weeks.

Conclusion

The implementation of our two-step screening resulted in a highly effective reduction of the work load for the Transfusion medicine staff: 970 of 1240 (78.2%) callers could quite easily be identified as not eligible for plasma donation for several reasons. In a more detailed analysis of our screening results we are planning on adapting and specifying our screening algorithm to provide an effective time-saving tool for situations where a highly frequented donor acquisition is needed.